Sentences with phrase «in multiple myeloma»

«Therefore, the targeting of Runx2 expression in multiple myeloma cells may represent a new therapeutic strategy for the treatment of aggressive multiple myeloma.»

Darbepoietin - Alfa after High - Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study

In this interview we discuss how relapse in multiple myeloma manifests and treatment options for relapsed / refractory patients.

This is the first study of the Runx2 expression in multiple myeloma, a cancer of the white blood cells that causes an estimated 11,000 deaths a year in the U.S., says Yang, who is also a scientist in UAB's Comprehensive Cancer Center and Center for Metabolic Bone Disease.

A series of experiments in the multiple myeloma study, with both animal models and cells from human patients, highlights the role of the transcription factor Runx2 to express bone - related genes in myeloma cells — genes that normally exist in bone residential cells, such as bone - forming osteoblasts and osteocytes, and the bone - resorbing osteoclast cells.

A promising avenue of clinical research in multiple myeloma is the use of immune checkpoint inhibitors.

The current study, which has accrued 32 patients to date, is the first in - human study of daratumumab in multiple myeloma patients.

The only documented long - term complete remissions reported in multiple myeloma patients have occurred with allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are transplanted into the patient (host) with multiple myeloma.

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

From a pure business perspective, however, troubles in multiple myeloma are unlikely to derail Keytruda's momentum considering its approvals in much more common cancers.

Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.

In their current study, the team investigated ADAR1's role in multiple myeloma.

They are also testing inhibitors of JAK2, a molecule that influences ADAR1 activity, for their ability to eliminate cancer stem cells in multiple myeloma models.

Using their new model, Jamieson, Crews and team found that two events converge to activate ADAR1 in multiple myeloma — a genetic abnormality and inflammatory cues from the surrounding bone marrow tissue.

Figure on the right: Bortezomib treatment is significantly less effective in multiple myeloma patients who have suppressed expression of a 19s proteasome cap subunit.

This gene is known to be highly active in multiple myeloma and many other cancers, raising the possibility that strategies to shut it down could be effective against a variety of tumors.

The researchers used the Runx2 knock - in and knock - down cells to show that Runx2 overexpression activates the Akt / β - catenin / Survivin signaling system in the multiple myeloma cells.

In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cells.

«I'm predicting an increase in multiple myeloma,» said Edward Medina, M.D., Ph.D., «and with the obesity problems we see in the Hispanic population, there could be a serious health disparity on the horizon.»

Their presentation is entitled «High expression of AF1q is an adverse prognostic factor and a prediction marker of extramedullary disease in multiple myeloma.»

«We are excited by the work of Dr. Pourdehnad and colleagues and believe these results are an important advance in understanding the role of myc pathway dysregulation in multiple myeloma, and ultimately allow for the development of therapeutic strategies to address it,» said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the research.

After being infused back into patients» bodies, these newly built cells both multiply and seek out a peptide expressed by the antigens NY - ESO - 1 and LAGE - 1 found in multiple myeloma cancer cells.

«T - cell receptor therapy achieves encouraging clinical responses in multiple myeloma: NY - ESO T cell receptor therapy found to be safe, with no cytokine release syndrome cases.»

«Narrow subset of cells is responsible for metastasis in multiple myeloma, study finds.»

«We believe that the new criteria will rectify the situation where we were unable to use the considerable advances in multiple myeloma therapy prior to organ damage.

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels

Data from an on - going early stage phase I / II trial of daratumumab in multiple myeloma continues to show promising activity.

Another modified peptide POL6326 is in phase II clinical trial in hematopoietic stem cell mobilization in multiple myeloma [128].

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Targeted therapy — the most recent advancement in multiple myeloma treatment, targeted therapies detect and attack cancer cells without damaging normal cells

Kenneth R. Carson, MD, PhD Washington University in St. Louis Saint Louis, MO Can We Move Towards Prevention in Multiple Myeloma?

Both the local effects (pain and inability to function normally) and distant spread may cause significant distress to your pet, particularly in multiple myeloma.

The study, published December 4 in Nature Communications, also suggests that a class of commercially available drugs could be used to dampen ADAR1 activity, and ultimately prevent progression or relapse in multiple myeloma.

In the multiple myeloma study, normal weight is defined as a BMI of no more than 25 kg / m2, and morbidly obese is in the range of 35 to 40 kg / m2.

She then pursued postdoctoral training at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL, where she began her research in multiple myeloma.

«In multiple myeloma, high levels of enzyme ADAR1 are associated with reduced survival.»

But in multiple myeloma, plasma cells grow out of control in the bone marrow, crowding out healthy cells.

The study, «Lenalidomide (LEN) maintenance (MNTC) after high - dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta - analysis (MA) of overall survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma Cell Dyscrasia oral abstract session Friday, June 3.

In multiple myeloma, normal plasma cells transform into malignant myeloma cells and produce large quantities of toxic abnormal immunoglobulin called monoclonal protein that can damage multiple organs.

Safety, Pharmacokinetics and Stem Cell Mobilization of TG - 0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients.

In multiple myeloma, abnormal plasma cells (myeloma cells) build up in the bone marrow and form tumors in many bones of the body.

Inspired by XBP - 1's roles in maintaining a homeostatic ER, the lab began to examine the role of XBP - 1 in B - cell leukemia whose progression does not require dramatic ER expansion like that in multiple myeloma.

In multiple myeloma, this M component is found in circulation in the blood and sometimes different organs or bones of the body are also affected.